HKSE - Delayed Quote HKD
Zai Lab Limited (9688.HK)
At close: October 16 at 4:08 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
322,711.000
266,719.000
215,040.000
144,312.000
48,958.000
--
Cost of Revenue
119,568.000
95,816.000
74,018.000
52,239.000
16,736.000
--
Gross Profit
203,143.000
170,903.000
141,022.000
92,073.000
32,222.000
--
Operating Expense
551,392.000
545,043.000
533,908.000
788,024.000
334,023.000
--
Operating Income
-348,249.000
-374,140.000
-392,886.000
-695,951.000
-301,801.000
--
Net Non Operating Interest Income Expense
37,859.000
39,797.000
14,582.000
2,190.000
4,939.000
--
Other Income Expense
12,061.000
-277.000
-64,761.000
-9,653.000
29,076.000
--
Pretax Income
-298,329.000
-334,620.000
-443,065.000
-703,414.000
-267,786.000
--
Earnings from Equity Interest Net of Tax
--
--
-221.000
-1,057.000
-1,119.000
--
Net Income Common Stockholders
-298,329.000
-334,620.000
-443,286.000
-704,471.000
-268,905.000
--
Diluted NI Available to Com Stockholders
-298,329.000
-334,620.000
-443,286.000
-704,471.000
-268,905.000
--
Basic EPS
-0.31
-0.35
-0.46
-0.76
-0.35
--
Diluted EPS
-0.31
-0.35
-0.46
-0.76
-0.35
--
Basic Average Shares
972,094.840
966,394.130
958,067.140
929,921.120
776,677.430
--
Diluted Average Shares
972,094.840
966,394.130
958,067.140
929,921.120
776,677.430
--
Total Operating Income as Reported
-353,924.000
-366,573.000
-404,357.000
-700,064.000
-301,801.000
--
Total Expenses
670,960.000
640,859.000
607,926.000
840,263.000
350,759.000
--
Net Income from Continuing & Discontinued Operation
-298,329.000
-334,620.000
-443,286.000
-704,471.000
-268,905.000
--
Normalized Income
-308,470.000
-329,770.000
-386,883.000
-709,132.000
-290,564.000
--
Interest Income
38,464.000
39,797.000
14,582.000
2,190.000
5,120.000
--
Interest Expense
--
--
--
--
181.000
293.000
Net Interest Income
37,859.000
39,797.000
14,582.000
2,190.000
4,939.000
--
EBIT
-337,244.000
-374,140.000
-392,886.000
-695,951.000
-267,605.000
--
EBITDA
-326,914.000
-365,111.000
-384,659.000
-689,464.000
-262,965.000
--
Reconciled Cost of Revenue
119,568.000
95,816.000
74,018.000
52,239.000
16,736.000
--
Reconciled Depreciation
10,330.000
9,029.000
8,227.000
6,487.000
4,640.000
--
Net Income from Continuing Operation Net Minority Interest
-298,329.000
-334,620.000
-443,286.000
-704,471.000
-268,905.000
--
Total Unusual Items Excluding Goodwill
10,141.000
-4,850.000
-56,403.000
4,661.000
21,659.000
--
Total Unusual Items
10,141.000
-4,850.000
-56,403.000
4,661.000
21,659.000
--
Normalized EBITDA
-337,055.000
-360,261.000
-328,256.000
-694,125.000
-284,624.000
--
12/31/2019 - 9/28/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
184.000
-0.05%
6998.HK Genor Biopharma Holdings Limited
1.770
-1.67%
9969.HK InnoCare Pharma Limited
6.450
+1.10%
9995.HK RemeGen Co., Ltd.
15.000
0.00%
1801.HK Innovent Biologics, Inc.
43.850
-1.68%
1877.HK Shanghai Junshi Biosciences Co., Ltd.
13.600
+0.29%
6160.HK BeiGene, Ltd.
134.000
+0.53%
208340.KQ PharmAbcine, Inc.
0.0000
0.00%
6A3A.F Autolus Therapeutics plc
3.8600
+1.58%
086900.KQ Medy-Tox Inc.
180,100.00
-5.76%